Summary
75 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 17 USD is left as net profit.
- Revenue grew by 29% a year over the last 3 years.
- It holds more cash than debt: $317.4K against $95.5K.
- The share price is below the Bulios Fair Price.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- It earns only 5.0 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 9.2 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 85% a year over 5 years. Over the last 3 years it grew by 29% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 33 USD
- Research and development 16 USD
- Sales and administration 48 USD
- Taxes and other -15 USD
- Net profit 17 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 17 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Subscription Revenue 51%
- Shipping and Handling 49%
By region
The company reports no revenue by region.
Subscription Revenue brings in 51% of revenue.
Segments in detail